ClinicalTrials.gg
RecruitingNCT07650318Updated Sep 18, 2026

The Cognitive Protective Effect of VR-based Cognitive Training in Type 2 Diabetes Patients With Mild Cognitive Impairment

An interventional study of VR-Based Cognitive Training Plus Standard Diabetes Care and Traditional Paper-and-Pencil Cognitive Training Plus Standard Diabetes Care in Type 2 Diabetes Mellitus (T2DM) and Mild Cognitive Impairment (MCI), sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 1 site in China. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Diabetes Mellitus, Type 2 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School — 11 open to participants now, 12 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.

Planned enrollment
9th of 12
40 · median 59
Started
2026
with 2 others
No phase
8 of 19
4 open now
Primary completion
2027-12
later than 6 of 11 live
Registered
18th of 19
by date

Among the 19 studies in Diabetes Mellitus, Type 2 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 8 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 18th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

11 of the 19 studies in Diabetes Mellitus, Type 2 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Diabetes Mellitus, Type 2 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, or all of them as a file.
02

Study summary

A multi-center prospective, open-label, parallel-group randomized controlled trial is conducted to investigate the cognitive-protective efficacy of a novel, diabetes-specific virtual reality (VR)-based cognitive training system integrated with diet management modules, relative to frequency- and duration-matched traditional paper-and-pencil cognitive training, in adults aged 45-80 years with T2DM and amnestic/mixed mild cognitive impairment (MCI). A total of 40 eligible participants are randomly assigned 1:1 to either the intervention group (24 weeks of individualized VR training with dynamic difficulty, 2 sessions/week, 45-60 minutes/session) or the active control group (standardized paper-and-pencil cognitive tasks). All participants maintain stable glucose-lowering regimens for ≥3 months and receive standardized weekly diabetes health education. The primary endpoint is the between-group difference in the change in MoCA total score from baseline to the 24-week follow-up. Secondary endpoints include changes in individual cognitive domains (memory, executive function, attention, processing speed), Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Score , Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) Score , Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score, olfactory threshold/identification/recall, brain structural volumes and resting-state functional connectivity (assessed via 3.0T fMRI), glycemic control (HbA1c, fasting/postprandial glucose), lipid profile, body composition, sleep quality, anxiety and depressive symptoms, and diabetes self-management behaviors. The safety and participant adherence to the VR intervention are also systematically monitored.

Read the detailed description

As China's aging population continues to grow, type 2 diabetes Mellitus (T2DM) has become a serious health threat to the country's elderly. The risk of dementia rises rapidly with age among T2DM patients. Mild cognitive impairment (MCI) is a critical transitional stage between normal aging and dementia; early intervention can effectively slow disease progression and reduce the risk of developing dementia. Against this backdrop, non-pharmacological interventions such as cognitive training have become a key pillar of early intervention due to their high safety profile and ease of implementation. Traditional paper-and-pencil cognitive training is limited by the lack of immersive, real-world scenarios and unsatisfactory patient compliance. Virtual reality technology, with its immersive and interactive features, has shown favorable outcomes in cognitive rehabilitation for MCI patients. Nevertheless, specialized VR cognitive training programs tailored for T2DM combined with MCI are currently lacking.

This study aims to evaluate the cognitive-protective efficacy of a customized VR-based cognitive training system integrated with diabetes self-management modules in adults with T2DM and MCI. The system combines multi-sensory cognitive training with diabetes diet management education to improve cognitive function, metabolic parameters and diabetes self-management ability simultaneously. The safety and participant adherence of this customized VR training system are also verified systematically in the trial.

A total of 40 eligible participants are enrolled and randomized in a 1:1 ratio to either the VR cognitive training group or the traditional paper-and-pencil cognitive training group. The intervention period lasts 24 weeks. All participants maintain stable glucose-lowering regimens for no less than 3 months before enrollment and throughout the trial, and receive standardized weekly diabetes health education. Weekly follow-ups are conducted via verbal communication, telephone or WeChat to monitor glycemic control, adverse events and training adherence.

Participants in the VR cognitive training group use a customized VR cognitive training system developed by the research team. The system is equipped with an HTC VIVE Pro Eye head-mounted display, handheld controllers, spatial positioning base stations and a 360° rotating seat, and its supporting software is developed based on the Unity3D engine. Individualized training plans are generated according to participants' metabolic parameters including height, weight, physical activity level and diabetes duration, and training difficulty is adjusted dynamically based on task completion rate and response time of each session. The training consists of four core modules: (1) VR supermarket/canteen module, which combines diabetes diet management training with executive function, memory and calculation ability training; (2) multi-sensory object finding and difference detection module for the training of attention, visual span and cross-modal association ability; (3) mindfulness healing garden module, which relieves negative emotions through virtual natural scenes, soothing audio and relaxing scents; (4) comprehensive cognitive training module targeting memory and processing speed via digit span test, trail making test and other tasks. Training is delivered twice a week, with each session lasting 45 to 60 minutes. Participants in the control group receive frequency- and duration-matched paper-and-pencil cognitive training under full guidance from research staff throughout each session.

Assessments are performed at baseline and upon completion of the 24-week intervention, with interim follow-ups arranged at the 8th, 16th and 24th weeks to evaluate training adherence and diabetes self-management ability. The primary endpoint is the between-group difference in the change in Montreal Cognitive Assessment (MoCA) total score from baseline to week 24. Secondary endpoints cover changes in domain-specific cognitive functions (assessed by the Repeatable Battery for the Assessment of Neuropsychological Status [RBANS], digit span test, Stroop Color-Word Test and Trail Making Test), olfactory function (olfactory threshold, identification and recall scores), brain structural measurements and resting-state functional network connectivity (assessed via 3.0T functional magnetic resonance imaging [fMRI]), glycemic and lipid metabolic parameters (HbA1c, fasting and postprandial blood glucose, insulin, C-peptide and lipid profile), body composition, sleep quality, anxiety and depressive symptoms, as well as diabetes self-management behaviors. Safety assessments include monitoring the type, incidence, severity and causality of adverse events throughout the trial, together with regular detection of vital signs and laboratory indicators including liver and kidney function.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
  • Mild Cognitive Impairment (MCI)

Keywords

  • Cognition
  • Cognitive training
  • Functional MRI
  • Virtual reality (VR) technology
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 45-80 years; gender is not restricted;
  2. Participants must meet the diagnostic criteria for diabetes outlined in the *Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition)*, namely: patients exhibit typical symptoms of diabetes and meet one of the following conditions: 1) ≥ 6.5%; 2) Fasting blood glucose ≥7.0 mmol/L. Fasting is defined as no caloric intake for at least 8 hours; 3) 2-hour postprandial blood glucose ≥11.1 mmol/L following an oral glucose tolerance test; 4) Random blood glucose ≥11.1 mmol/L;
  3. Stable glycemic control regimen for 3 months or longer;
  4. Completed a systematic neuropsychological assessment and meets Petersen criteria for Mild Cognitive Impairment, satisfying the following conditions: 1) The patient or a caregiver subjectively perceives a decline in cognitive function; 2) Assessment results indicate impairment in one or more cognitive domains; 3) There is mild impairment in complex instrumental activities of daily living, but the patient maintains independence in basic activities of daily living; 4) Does not yet meet the diagnostic criteria for dementia;
  5. Has an educational level of elementary school or higher and is able to cooperate in completing the assessment, VR training, and various examinations;
  6. Cooperate in undergoing magnetic resonance imaging (MRI) examinations;
  7. Voluntarily participates in this study, signs an form, and is able to comply with the study protocol requirements to complete follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Suffering from other dementia-related neurological disorders (such as Alzheimer's disease, Parkinson's disease, etc.) or severe mental illness;
  2. History of central nervous system disorders, including traumatic brain injury, intracranial hemorrhage, acute cerebral infarction, etc.;
  3. Severe sinusitis, space-occupying lesions in the nasopharynx, or congenital disorders affecting the sense of smell,or a history of trauma;
  4. Glaucoma, severe dry eye syndrome, uncorrected strabismus, severe diabetic retinopathy,or severe motion sickness, making the user unable to tolerate VR devices;
  5. History of acute diabetic complications within the past 3 months (diabetic ketoacidosis, hyperglycemic hyperosmolar state, severe hypoglycemia, etc.);
  6. Severe impairment of vital organ function, including cardiac, hepatic, or renal dysfunction;
  7. Pregnant or breastfeeding women, or women planning to become pregnant during the study;
  8. for MRI scans, such as the presence of metallic prostheses, pacemakers, cochlear implants, or other metallic implants, or claustrophobia;
  9. Participation in other clinical trials currently or within the past 3 months;
  10. Known or suspected history of allergy to study-related materials;
  11. Currently taking medications intended to improve cognitive function.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    VR-Based Cognitive Training Plus Standard Diabetes Care

    Participants will receive customized virtual reality (VR)-based cognitive training in addition to standard diabetes care and weekly structured health education for 24 weeks.

    Device: VR-Based Cognitive Training Plus Standard Diabetes Care

  • Active comparator
    Traditional Paper-and-Pencil Cognitive Training Plus Standard Diabetes Care

    Device: Traditional Paper-and-Pencil Cognitive Tasks Participants will complete standardized paper-and-pencil cognitive training tasks targeting the same cognitive domains as the VR group. Training will be administered twice weekly for 45-60 minutes per session for 24 weeks, with full guidance from trained research staff throughout each session to ensure standardization.

    Other: Traditional Paper-and-Pencil Cognitive Training Plus Standard Diabetes Care

Interventions

  • DeviceVR-Based Cognitive Training Plus Standard Diabetes Care

    Device: Customized VR Cognitive Training System Participants will receive individualized VR cognitive training using the research team-developed system, which consists of an HTC VIVE Pro Eye head-mounted display, handheld controllers, spatial positioning base stations, and a 360° rotating seat, with software developed on the Unity3D engine. Training plans are generated based on patients' metabolic parameters (height, weight, physical activity level, diabetes duration), and difficulty is dynamically adjusted according to each session's task completion rate and response time. The training includes four core modules: (1) VR supermarket/canteen (integrating diabetes diet management); (2) multi-sensory object finding/difference detection; (3) mindfulness healing garden (multi-sensory emotional regulation); (4) comprehensive cognitive training (digit span, trail making tests). Training will be administered twice weekly for 45-60 minutes per session for 24 weeks.

  • OtherTraditional Paper-and-Pencil Cognitive Training Plus Standard Diabetes Care

    Device: Traditional Paper-and-Pencil Cognitive Tasks Participants will complete standardized paper-and-pencil cognitive training tasks targeting the same cognitive domains (memory, attention, executive function, processing speed) as the VR group. Training will be administered twice weekly for 45-60 minutes per session for 24 weeks, with full guidance from trained research staff throughout each session to ensure standardization.

06

What researchers measure

Primary outcomes

  1. Change in cognitive function (evaluated by MoCA score)

    Whether MoCA scores in the two groups of Type 2 diabetes mellitus patients with MCI after intervention were different from those before treatment and the difference of changes between the two groups. The MoCA scale evaluates overall cognitive function, with a total score of 30. Generally, subjects scoring ≥26 points are considered as normal cognition,while between 19-25 points as mild cognitive impairment. An extra point is added If the subject has less than 12 years of education.

    Time frame: Baseline , Week24

Secondary outcomes

  1. Chang in Immediate Memory(evaluated by RBANS score)

    The immediate memory assessment primarily consists of two tests: (1) vocabulary learning and (2) story memory. The vocabulary learning task involves five rounds of serial learning to assess the ability to progressively encode verbal information; the story memory task involves the immediate retelling of a logical story to assess the ability to encode contextual information. All raw scores from the subtests must be converted to age-corrected standard scores (mean = 10, standard deviation = 3) to eliminate the influence of age on cognitive scores; the score for each cognitive domain is calculated by summing the age-corrected standard scores of its subordinate subtests and then directly converting this sum to the standard score for that cognitive domain using a conversion table (mean = 10, standard deviation = 3).

    Time frame: Baseline , Week24

  2. Change in Visual-Spatial/Structural Ability(evaluated by RBANS score)

    The Visual-Spatial/Structural Ability Assessment primarily consists of two tests: (1) Figure Reproduction and (2) Line Orientation. Figure Reproduction requires the subject to trace complex geometric figures, assessing visuomotor coordination and spatial structuring abilities; Line Orientation requires matching lines with identical angles, assessing the ability to judge two-dimensional spatial relationships. All raw scores from the subtests must be converted to age-corrected standard scores (mean = 10, standard deviation = 3) to eliminate the influence of age on cognitive scores; the score for each cognitive domain is calculated by summing the age-corrected standard scores of its subordinate subtests and then directly converting this sum to the standard score for that cognitive domain using a conversion table (mean = 10).

    Time frame: Baseline , Week24

  3. Change in verbal function (evaluated by RBANS score)

    The verbal function assessment primarily consists of two tests: (1) Picture Naming and (2) Semantic Fluency (Animal Naming). The Picture Naming test involves naming 30 pictures of common objects to assess vocabulary retrieval speed; the Semantic Fluency test involves naming as many animals as possible within one minute (a type of category fluency) to assess the activation and retrieval capabilities of the semantic network. All raw scores from the subtests must be converted to age-corrected standard scores (mean = 10, standard deviation = 3) to eliminate the influence of age on cognitive scores; the score for each cognitive domain is calculated by summing the age-corrected standard scores of its subordinate subtests and then directly converting this sum to the standard score for that cognitive domain using a conversion table (mean = 10, standard deviation = 3).

    Time frame: Baseline , Week24

  4. Change in delayed memory(evaluated by RBANS score)

    The delayed memory assessment primarily consists of four tests: (1) Delayed Word Recall, (2) Delayed Story Recall, (3) Delayed Picture Recall, and (4) Delayed Word Recognition. The Delayed Word Recognition task requires participants to identify 10 previously learned words from a set of 20 distractor words, thereby assessing the integrity of memory storage. The core assessment functions include the ability to store information long-term, the ability to retrieve memories, and the ability to consolidate memories; All raw scores from the subtests must be converted to age-corrected standard scores (mean = 10, standard deviation = 3) to eliminate the influence of age on cognitive scores; the score for each cognitive domain is calculated by summing the age-corrected standard scores of its subordinate subtests and then directly converting this sum to the standard score for that cognitive domain using a conversion table (mean = 10, standard deviation = 3).

    Time frame: Baseline , Week24

  5. Change in attention(evaluated by RBANS score)

    The attention assessment primarily consists of two tests: (1) Digit Span (including forward and backward subtests) and (2) Digit Coding. Digit Coding requires participants to pair numbers with symbols one-to-one within 90 seconds, assessing visual information processing speed and visuomotor coordination. The core assessment functions include immediate auditory memory span, auditory working memory, visual information processing speed, and visuomotor coordination; All raw scores from the subtests must be converted to age-corrected standard scores (mean = 10, standard deviation = 3) to eliminate the influence of age on cognitive scores; the score for each cognitive domain is calculated by summing the age-corrected standard scores of its subordinate subtests and then directly converting this sum to the standard score for that cognitive domain using a conversion table (mean = 10, standard deviation = 3).

    Time frame: Baseline , Week24

  6. Change in Overall Cognitive Function(evaluated by RBANS score)

    The RBANS Overall Cognitive Function score is calculated by summing the standard scores from the five cognitive domains described above; The core assessment focuses on the subject's overall cognitive functioning level and the severity of cognitive impairment. After summing the standard scores from the five cognitive domains, the total is directly converted using a look-up table to a Total Scale Score (TSS; mean = 100, standard deviation = 15). This scoring system aligns with internationally accepted IQ scoring systems and provides an intuitive reflection of the subject's overall cognitive status.

    Time frame: Baseline , Week24

  7. Changes in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Scores

    The changes in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) scores from baseline to week 24 will be compared between the VR cognitive training group and the traditional cognitive training group. The score range is 0 to 18, with higher scores indicating more severe cognitive and functional impairment.

    Time frame: Baseline, 24 weeks

  8. Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) Score Change

    The change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) score from baseline to week 24 will be compared between the VR cognitive training group and the traditional cognitive training group. The score ranges from 0 to 85, with higher scores indicating more severe cognitive impairment.

    Time frame: Baseline, 24 weeks

  9. Change in Diabetes Self-Care Activities (SDSCA) Score

    The Summary of Diabetes Self-Care Activities (SDSCA) assessment primarily consists of 11 items across 6 dimensions: general diet, healthy eating, regular exercise, blood glucose monitoring, foot care, and medication adherence. Its core assessment function is to measure the frequency with which people with diabetes have performed various self-management behaviors over the past 7 days; All items are scored on a 0-7 scale (representing the number of days the behavior was performed over the past 7 days). The score for each dimension is calculated as the mean of the corresponding items, and the total score is the mean of all items, with a score range of 0-7. A higher score indicates better adherence to diabetes self-management behaviors.

    Time frame: Baseline , Week8, week16, Week24

  10. Change in Resting-State Functional MRI

    Assessment of baseline brain functional state. Key metrics: amplitude of low-frequency fluctuations (ALFF), regional coherence (ReHo), and functional connectivity within the default mode network and executive control network. Data are corrected for head motion and physiological noise, and data with excessive head motion (translation \> 2 mm / rotation \> 2°) are excluded.

    Time frame: Baseline , Week24

  11. Change of Olfactory function

    Whether the scores of olfactory threshold, identification and memory of the two groups after intervention were higherthan those before treatment and the difference of changes between the two groups. Olfactory testing was performed using Olfactory Function Assessment by Computerized Testing (OLFACT) (Osmic Enterprises, Inc.). Based on the University of Pennsylvania Smell Identification Test (UPSIT), OLFACT tests were computerized, standardized, and self-administered. Higher scores indicated better ability to detect odors. Threshold testing was performed by a series of binary dilutions of n- butanol solution in light mineral oil, and scores ranged from 1 to 14. Identification and memory tests included two tasks: task A with 10 different odors, and task B with 20 odors (with 10 same odors in the task A). Each participant was asked to identify each odor from four pictures in tasks A and B and to indicate whether each was old or new in task B. There was a 10-min break in-between.

    Time frame: Baseline , Week24

  12. Change in blood glucose

    Change in fasting blood glucose from baseline to Week 24 will be assessed using laboratory testing.

    Time frame: Baseline, Week 24

  13. Change in Glycated Hemoglobin

    Change in glycated hemoglobin (HbA1c) from baseline to Week 24 will be assessed using laboratory testing.

    Time frame: Baseline, Week 24

  14. Change in liver function

    Change in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) from baseline to Week 24 will be assessed using laboratory testing.

    Time frame: Baseline, Week 24

  15. Change in kidney function

    Change in Serum Creatinine(Ucr),Urea,Uric Acid(UA),Glomerular Filtration Rate (eGFR) from baseline to Week 24 will be assessed using laboratory testing.

    Time frame: Baseline, Week 24

  16. Change in blood lipid levels

    Change in high-density lipoprotein cholesterol (HDL-C) , low-density lipoprotein cholesterol (LDL-C), Total cholesterol(TC), triglyceridesfrom(TC) from baseline to Week 24 will be assessed using laboratory testing.

    Time frame: Baseline, Week 24

  17. Change in insulin and C-peptide levels at fasting and 120 minutes after a meal

    Change in insulin and C-peptide levels at fasting and 120 minutes after a meal from baseline to Week 24 will be assessed using laboratory testing.

    Time frame: Baseline, Week 24

  18. Percent Change in Body Weight From Baseline

    Percent change in body weight from baseline to Week 24 will be compared between two groups .

    Time frame: Baseline, Week 24

  19. Change in waist and hip measurements

    Change in waist and hip measurements from baseline to Week 24 will be assessed using standardized anthropometric measurement.

    Time frame: Baseline, Week 24

  20. Change in Body Composition and Fat Distribution

    Changes in body composition and fat distribution will be assessed by body fat percentage using anthropometric measurements and body composition analysis.

    Time frame: Baseline, Week 24

  21. Change in Controlled Attenuation Parameter

    Change in controlled attenuation parameter (CAP) from baseline to Week 24 will be assessed using transient elastography.

    Time frame: Baseline, Week 24

  22. Change in Liver Stiffness Measurement

    Change in liver stiffness measurement (LSM) from baseline to Week 24 will be assessed using transient elastography.

    Time frame: Baseline, Week 24

  23. Change in Hospital Anxiety and Depression Scale (HADS) Score

    The Hospital Anxiety and Depression Scale (HADS) primarily consists of two subscales with a total of 14 items: (1) the Anxiety Subscale (HADS-A, 7 items); (2) Depression Subscale (HADS-D, 7 items); Its core function is to screen for and quantify the severity of anxiety and depressive states in non-psychiatric patients, effectively distinguishing between symptoms of physical illness and those of mood disorders; All items are scored on a 4-point scale ranging from 0 to 3. The total score for each subscale ranges from 0 to 21, and the total scale score is the sum of the two subscales (0-42). Higher scores indicate more severe anxiety or depressive symptoms. Clinical cutoffs: 0-7 points is normal, 8-10 points indicates a suspected mood disorder, and 11-21 points indicates a definite mood disorder.

    Time frame: Baseline , Week24

  24. Change in Self-Rating Anxiety Scale (SAS) Score

    The Self-Rating Anxiety Scale (SAS) primarily consists of 20 items covering subjective feelings of anxiety, physical symptoms, restlessness, and autonomic dysfunction; its core function is to assess the severity of participants' subjective anxiety symptoms and their dynamic changes before and after intervention; All items are rated on a 4-point scale from 1 to 4 (with 5 items reverse-scored). Raw scores are multiplied by 1.25 and rounded to the nearest whole number to obtain a standard score, with a range of 25-100 points; a higher score indicates more severe anxiety symptoms; Clinical cutoff scores: \<50 points is normal, 50-59 points is mild anxiety, 60-69 points is moderate anxiety, and ≥70 points is severe anxiety.

    Time frame: Baseline , Week24

  25. Change in Functional Activities Questionnaire-9 (FAQ-9) Score

    The Functional Activities Questionnaire-9 (FAQ-9) primarily assesses nine items related to instrumental activities of daily living: using the telephone, shopping, meal preparation, housework, laundry, using public transportation, taking medication regularly, managing finances, and going out alone; The core assessment function is the subject's instrumental activities of daily living (IADL) ability, making it a sensitive tool for distinguishing between normal aging and functional impairment caused by mild cognitive impairment; All items are scored on a 4-point scale ranging from 0 to 3 (0 = completely independent; 3 = completely dependent on others), with a total score ranging from 0 to 27; a higher score indicates more severe impairment in instrumental activities of daily living; the clinical cutoff is ≥5, indicating significant functional impairment.

    Time frame: Baseline , Week24

  26. Change in Pittsburgh Sleep Quality Index (PSQI) Score

    The Pittsburgh Sleep Quality Index (PSQI) primarily assesses seven core components: subjective sleep quality, time to fall asleep, total sleep time, sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction. Its core function is to provide a comprehensive evaluation of overall sleep quality and various sleep-related issues over the past month. Each component is scored on a scale of 0-3, with a total score ranging from 0 to 21. A higher score indicates poorer sleep quality; the clinical cutoff is ≥7, indicating the presence of a clinically significant sleep disorder.

    Time frame: Baseline , Week24

  27. Changes in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Scores

    The ADCS-ADL is a scale consisting of 23 items, including 6 basic ADL (bADL) items and 17 instrumental ADL (IADL) items. The change in ADCS-ADL scores from baseline to week 24 will be compared between the VR cognitive training group and the traditional cognitive training group.The total score ranges from 0 to 78, with lower scores indicating greater severity of cognitive impairment.

    Time frame: Baseline,24 weeks

Other outcomes

  1. Change in Simulator Sickness Questionnaire (SSQ)

    Assesses the severity of VR-related motion sickness, comprising 16 items related to physical discomfort (headache, dizziness, nausea, etc.). It uses a 4-point rating scale from 0 to 3 (0 = no symptoms, 3 = severe), with a total score ranging from 0 to 48. Cutoff scores: \<5 points = no discomfort; 5-12 points = mild; 13-24 points = moderate (requires pause for adjustment); ≥25 points = severe (terminate intervention).

    Time frame: Baseline , Week 8 , Week 16 , Week24

  2. Change in VR Experience Acceptance Scale

    Based on the Technology Acceptance Model, this scale comprises 15 items across 5 dimensions: perceived usefulness, perceived ease of use, perceived enjoyment, user experience, and intention to use. A 5-point Likert scale is used (1 = strongly disagree, 5 = strongly agree). Dimensional and total scores are calculated as the mean of the corresponding items; higher scores indicate better acceptance.

    Time frame: Baseline, Week 8, Week 16, Week 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 18 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jun 16, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Jun 1, 2028
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07650318
Collaborators
Nanjing Lanyuan Community Health Service Center, Nanjing Meiyuan Xincun Community Health Service Center, Nanjing Dayingbi Community Health Service Center
Responsible party
Yan Bi (Chief Physician, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School) — Principal investigator
First posted
Jun 16, 2026
Start date
Jun 1, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Sep 18, 2026

Study contacts

Yan Bi, MD, PhD
Contact
biyan@nju.edu.cn
6-25-83-105302
Zhou Zhang, MD, PhD
Contact
zhangzhou@smail.nju.edu.cn
(86) 25-83106666

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion